Merck & Co., Inc. $MRK Shares Bought by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 37.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 897,288 shares of the company’s stock after acquiring an additional 246,759 shares during the period. Merck & Co., Inc. accounts for 0.7% of Mediolanum International Funds Ltd’s holdings, making the stock its 22nd biggest position. Mediolanum International Funds Ltd’s holdings in Merck & Co., Inc. were worth $70,509,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC increased its position in Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares in the last quarter. Kilter Group LLC purchased a new stake in Merck & Co., Inc. in the second quarter valued at approximately $27,000. Bare Financial Services Inc grew its holdings in Merck & Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after purchasing an additional 125 shares during the period. Barnes Dennig Private Wealth Management LLC increased its position in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the last quarter. Finally, Evolution Wealth Management Inc. purchased a new position in Merck & Co., Inc. during the second quarter worth approximately $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 8,614 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the sale, the executive vice president owned 24,578 shares in the company, valued at $2,054,475.02. This represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $110.24 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.66 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $112.90. The business has a 50 day moving average price of $105.20 and a two-hundred day moving average price of $91.94. The firm has a market cap of $273.62 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 1.52 and a beta of 0.29.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. Sell-side analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is currently 44.91%.

Analysts Set New Price Targets

Several analysts have recently issued reports on MRK shares. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Scotiabank raised their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a report on Thursday, December 4th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a research note on Thursday, January 8th. Finally, TD Cowen increased their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Eight investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $114.53.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer?term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector?specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A?related costs could depress near?term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near?term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.